Trial Profile
A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs ADG 106 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Adagene
- 15 Oct 2022 Status changed from active, no longer recruiting to completed.
- 22 Jul 2022 Planned End Date changed from 30 Jun 2022 to 31 Aug 2022.
- 11 Jan 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.